{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T04:10:36Z","timestamp":1758687036244,"version":"3.44.0"},"reference-count":115,"publisher":"Wiley","issue":"18","license":[{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015738","name":"Mary och Georg C. Ehrnrooths Stiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012623","name":"Federation of European Biochemical Societies","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012623","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004756","name":"Emil Aaltosen S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004756","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004212","name":"P\u00e4ivikki ja Sakari Sohlbergin S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004212","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013510","name":"Silm\u00e4- ja kudospankkis\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013510","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002341","name":"Research Council of Finland","doi-asserted-by":"publisher","award":["346295"],"award-info":[{"award-number":["346295"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006306","name":"Sigrid Jus\u00e9liuksen S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006306","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014438","name":"Business Finland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014438","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["febs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["FEBS Letters"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:sec><jats:label\/><jats:p>Retinitis pigmentosa (RP) is a heterogeneous group of inherited retinal degenerative diseases caused by mutations in over 90 genes. The complexity of its genetic background and economic barriers limit the broad application of targeted gene therapies. Therefore, general pharmacological strategies to slow disease progression, regardless of the underlying mutation, are needed. Cyclic nucleotide second messengers, such as cyclic guanosine monophosphate (cGMP) and cyclic adenosine monophosphate (cAMP), are important for normal retinal function. This includes phototransduction, for which cGMP signaling is essential. Dysregulation of the cyclic nucleotide systems is associated with retinal degeneration, and the inhibition of cGMP or cAMP signaling has shown beneficial effects in several retinal degeneration disease models. Here, we propose these systems as drug targets for RP.<\/jats:p><\/jats:sec><jats:sec><jats:label\/><jats:p>\n<jats:boxed-text content-type=\"box\" position=\"anchor\"><jats:caption><jats:title>Impact statement<\/jats:title><\/jats:caption><jats:p>This perspective proposes targeting cyclic nucleotide signaling (cGMP and cAMP) as a mutation\u2010independent therapeutic strategy for retinitis pigmentosa, offering broad potential for disease\u2010modifying treatment potentially through drug repurposing and novel drug delivery systems.<\/jats:p><\/jats:boxed-text>\n<\/jats:p><\/jats:sec>","DOI":"10.1002\/1873-3468.70107","type":"journal-article","created":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T13:24:01Z","timestamp":1752067441000},"page":"2557-2570","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cyclic nucleotide signaling as a drug target in retinitis pigmentosa"],"prefix":"10.1002","volume":"599","author":[{"given":"Katri","family":"Vainionp\u00e4\u00e4","sequence":"first","affiliation":[{"name":"School of Pharmacy, Faculty of Health Sciences University of Eastern Finland  Kuopio Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed B.","family":"Montaser","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Faculty of Health Sciences University of Eastern Finland  Kuopio Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0388-832X","authenticated-orcid":false,"given":"Henri","family":"Leinonen","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Faculty of Health Sciences University of Eastern Finland  Kuopio Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,7,9]]},"reference":[{"doi-asserted-by":"publisher","key":"e_1_2_11_2_1","DOI":"10.1016\/S0140-6736(06)69740-7"},{"doi-asserted-by":"publisher","key":"e_1_2_11_3_1","DOI":"10.1186\/gm155"},{"key":"e_1_2_11_4_1","first-page":"30","article-title":"Ophthalmology and clinical research retinitis pigmentosa: disease encumbrance in the eurozone","volume":"2","author":"Vaidya P","year":"2015","journal-title":"Int J Ophthalmol Clin Res"},{"unstructured":"RetNet.orgSummaries of Genes and Loci Causing Retinal Diseases. Accessed 22.4.2025.","key":"e_1_2_11_5_1"},{"doi-asserted-by":"publisher","key":"e_1_2_11_6_1","DOI":"10.1080\/13816810.2021.1913610"},{"unstructured":"LuxturnaU.S. Food and Drug Administration. Accessed 25.4.2025.https:\/\/www.fda.gov.","key":"e_1_2_11_7_1"},{"unstructured":"Safety and Tolerability of Intravitreal Administration of VG901 in Patients With Retinitis Pigmentosa Due to Mutations in the CNGA1 Gene. Clinicaltrials.gov NCT06291935.","key":"e_1_2_11_8_1"},{"unstructured":"Promising ROd\u2010cone DYstrophy Gene TherapY (PRODYGY). Clinicaltrials.gov NCT05748873.","key":"e_1_2_11_9_1"},{"unstructured":"Safety and Efficacy Study in Patients With Retinitis Pigmentosa Due to Mutations in PDE6B Gene. Clinicaltrials.gov NCT03328130.","key":"e_1_2_11_10_1"},{"unstructured":"A First\u2010in\u2010human Proof of Concept Study of CPK850 in Patients With RLBP1 Retinitis Pigmentosa. Clinicaltrials.gov NCT03374657.","key":"e_1_2_11_11_1"},{"unstructured":"A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa (liMeliGhT). Clinicaltrials.gov NCT06388200.","key":"e_1_2_11_12_1"},{"unstructured":"A Study to Evaluate the Safety and Tolerability of QR\u20101123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene (AURORA). Clinicaltrials.gov NCT04123626.","key":"e_1_2_11_13_1"},{"unstructured":"4D\u2010125 in Patients With X\u2010Linked Retinitis Pigmentosa (XLRP). Clinicaltrials.gov NCT04517149.","key":"e_1_2_11_14_1"},{"unstructured":"Gene Therapy for RPGR Gene Mutation\u2010associated X\u2010linked Retinitis Pigmentosa. Clinicaltrials.gov NCT06492850.","key":"e_1_2_11_15_1"},{"unstructured":"Follow\u2010up Gene Therapy Trial for the Treatment of X\u2010linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene. Clinicaltrials.gov NCT04794101.","key":"e_1_2_11_16_1"},{"unstructured":"Gene Therapy for Subjects With RPGR Mutation\u2010associated X\u2010linked Retinitis Pigmentosa. Clinicaltrials.gov NCT05874310.","key":"e_1_2_11_17_1"},{"unstructured":"A Study Comparing Two Doses of AGTC\u2010501 in Male Participants With X\u2010linked Retinitis Pigmentosa Caused by RPGR Mutations (DAWN). Clinicaltrials.gov NCT06275620.","key":"e_1_2_11_18_1"},{"unstructured":"Long\u2010term Follow\u2010up Gene Therapy Study for RPGR\u2010XLRP. Clinicaltrials.gov NCT04312672.","key":"e_1_2_11_19_1"},{"unstructured":"A Study Comparing Two Doses of AGTC\u2010501 in Male Subjects With X\u2010linked Retinitis Pigmentosa Caused by RPGR Mutations (SKYLINE). Clinicaltrials.gov NCT06333249.","key":"e_1_2_11_20_1"},{"unstructured":"A Follow\u2010on Study for Second\u2010Eye Treatment for Participants Previously Treated With Gene Therapy for X\u2010Linked Retinitis Pigmentosa (XLRP). Clinicaltrials.gov NCT06646289.","key":"e_1_2_11_21_1"},{"unstructured":"Safety and Efficacy of rAAV2tYF\u2010GRK1\u2010RPGR in Subjects With X\u2010linked Retinitis Pigmentosa Caused by RPGR Mutations (HORIZON). Clinicaltrials.gov NCT03316560.","key":"e_1_2_11_22_1"},{"unstructured":"A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC\u2010501 in Participants With XLRP. Clinicaltrials.gov NCT04850118.","key":"e_1_2_11_23_1"},{"unstructured":"Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene (LUNA). Clinicaltrials.gov NCT06627179.","key":"e_1_2_11_24_1"},{"doi-asserted-by":"publisher","key":"e_1_2_11_25_1","DOI":"10.2174\/157015908784533851"},{"doi-asserted-by":"publisher","key":"e_1_2_11_26_1","DOI":"10.3390\/genes11101120"},{"doi-asserted-by":"publisher","key":"e_1_2_11_27_1","DOI":"10.1006\/bbrc.1995.2686"},{"doi-asserted-by":"publisher","key":"e_1_2_11_28_1","DOI":"10.1006\/exer.2001.1037"},{"key":"e_1_2_11_29_1","first-page":"1655","article-title":"Retinal cAMP levels during the progression of retinal degeneration in rhodopsin P23H and S334ter transgenic rats","volume":"43","author":"Traverso V","year":"2002","journal-title":"Invest Ophthalmol Vis Sci"},{"doi-asserted-by":"publisher","key":"e_1_2_11_30_1","DOI":"10.1146\/annurev-pharmtox-010715-103033"},{"doi-asserted-by":"publisher","key":"e_1_2_11_31_1","DOI":"10.3390\/ijms221910809"},{"doi-asserted-by":"publisher","key":"e_1_2_11_32_1","DOI":"10.1038\/s41420-022-01185-0"},{"doi-asserted-by":"publisher","key":"e_1_2_11_33_1","DOI":"10.1016\/j.ymthe.2023.04.005"},{"doi-asserted-by":"publisher","key":"e_1_2_11_34_1","DOI":"10.1016\/j.mcpro.2024.100855"},{"doi-asserted-by":"publisher","key":"e_1_2_11_35_1","DOI":"10.1007\/s00424-006-0194-y"},{"doi-asserted-by":"publisher","key":"e_1_2_11_36_1","DOI":"10.3390\/ijms25063446"},{"doi-asserted-by":"publisher","key":"e_1_2_11_37_1","DOI":"10.3390\/genes10060453"},{"doi-asserted-by":"publisher","key":"e_1_2_11_38_1","DOI":"10.1038\/eye.1990.46"},{"doi-asserted-by":"publisher","key":"e_1_2_11_39_1","DOI":"10.1159\/000098015"},{"doi-asserted-by":"publisher","key":"e_1_2_11_40_1","DOI":"10.1016\/j.preteyeres.2019.07.005"},{"doi-asserted-by":"publisher","key":"e_1_2_11_41_1","DOI":"10.1093\/hmg\/ddv275"},{"doi-asserted-by":"publisher","key":"e_1_2_11_42_1","DOI":"10.3390\/ijms241311200"},{"doi-asserted-by":"publisher","key":"e_1_2_11_43_1","DOI":"10.1111\/j.1582-4934.2010.01201.x"},{"doi-asserted-by":"publisher","key":"e_1_2_11_44_1","DOI":"10.1371\/journal.pone.0015495"},{"doi-asserted-by":"publisher","key":"e_1_2_11_45_1","DOI":"10.1167\/iovs.61.10.25"},{"doi-asserted-by":"publisher","key":"e_1_2_11_46_1","DOI":"10.1097\/WNR.0000000000000145"},{"doi-asserted-by":"publisher","key":"e_1_2_11_47_1","DOI":"10.1038\/s41467-023-40655-6"},{"doi-asserted-by":"publisher","key":"e_1_2_11_48_1","DOI":"10.1038\/13508"},{"doi-asserted-by":"publisher","key":"e_1_2_11_49_1","DOI":"10.1016\/j.bbrc.2003.12.034"},{"doi-asserted-by":"publisher","key":"e_1_2_11_50_1","DOI":"10.1159\/000320500"},{"doi-asserted-by":"publisher","key":"e_1_2_11_51_1","DOI":"10.1155\/2013\/585729"},{"doi-asserted-by":"publisher","key":"e_1_2_11_52_1","DOI":"10.1093\/hmg\/ddx121"},{"doi-asserted-by":"publisher","key":"e_1_2_11_53_1","DOI":"10.1074\/jbc.RA118.004459"},{"doi-asserted-by":"publisher","key":"e_1_2_11_54_1","DOI":"10.1007\/978-1-4419-1399-9_56"},{"key":"e_1_2_11_55_1","first-page":"42","article-title":"Calcium channel blocker D\u2010cis\u2010diltiazem does not slow retinal degeneration in the PDE6B mutant rcd1 canine model of retinitis pigmentosa","volume":"25","author":"Pearce\u2010Kelling S","year":"2001","journal-title":"Mol Vis"},{"doi-asserted-by":"publisher","key":"e_1_2_11_56_1","DOI":"10.1038\/s41420-022-00897-7"},{"doi-asserted-by":"publisher","key":"e_1_2_11_57_1","DOI":"10.1007\/978-3-540-68964-5_8"},{"doi-asserted-by":"publisher","key":"e_1_2_11_58_1","DOI":"10.2174\/0929867321666140601201337"},{"key":"e_1_2_11_59_1","first-page":"2766","article-title":"Localization of cGMP\u2010dependent protein kinase isoforms in mouse eye","volume":"41","author":"Gamm D","year":"2000","journal-title":"Invest Ophthalmol Vis Sci"},{"doi-asserted-by":"publisher","key":"e_1_2_11_60_1","DOI":"10.1016\/j.ijms.2010.07.021"},{"doi-asserted-by":"publisher","key":"e_1_2_11_61_1","DOI":"10.1073\/pnas.1718792115"},{"doi-asserted-by":"publisher","key":"e_1_2_11_62_1","DOI":"10.1111\/j.1471-4159.2008.05822.x"},{"doi-asserted-by":"publisher","key":"e_1_2_11_63_1","DOI":"10.3390\/ijms242015277"},{"doi-asserted-by":"publisher","key":"e_1_2_11_64_1","DOI":"10.1021\/acs.jmedchem.4c00586"},{"unstructured":"EraLearnTranslating cGMP analogues into a treatment for retinitis pigmentosa EJPRD20\u2010101. 2nd EJP RD Joint Transnational Call for Rare Diseases Research Project (JTC 2020).https:\/\/www.era\u2010learn.eu accessed 29.4.2025.","key":"e_1_2_11_65_1"},{"doi-asserted-by":"publisher","key":"e_1_2_11_66_1","DOI":"10.3390\/pharmaceutics14102102"},{"doi-asserted-by":"publisher","key":"e_1_2_11_67_1","DOI":"10.1101\/cshperspect.a011148"},{"doi-asserted-by":"publisher","key":"e_1_2_11_68_1","DOI":"10.1038\/s41467-024-50033-5"},{"key":"e_1_2_11_69_1","article-title":"Epac1 inhibition ameliorates pathological angiogenesis through coordinated activation of notch and suppression of VEGF signaling","volume":"6","author":"Liu H","year":"2020","journal-title":"Sci Adv"},{"doi-asserted-by":"publisher","key":"e_1_2_11_70_1","DOI":"10.1073\/pnas.73.12.4442"},{"doi-asserted-by":"publisher","key":"e_1_2_11_71_1","DOI":"10.3390\/cells12081157"},{"doi-asserted-by":"publisher","key":"e_1_2_11_72_1","DOI":"10.1523\/JNEUROSCI.22-06-02063.2002"},{"doi-asserted-by":"publisher","key":"e_1_2_11_73_1","DOI":"10.1523\/JNEUROSCI.14-05-03083.1994"},{"doi-asserted-by":"publisher","key":"e_1_2_11_74_1","DOI":"10.1167\/iovs.19-26560"},{"doi-asserted-by":"publisher","key":"e_1_2_11_75_1","DOI":"10.1172\/JCI69076"},{"doi-asserted-by":"publisher","key":"e_1_2_11_76_1","DOI":"10.1126\/scisignal.aag0245"},{"doi-asserted-by":"publisher","key":"e_1_2_11_77_1","DOI":"10.1111\/jnc.14613"},{"doi-asserted-by":"publisher","key":"e_1_2_11_78_1","DOI":"10.1074\/jbc.M111.315432"},{"doi-asserted-by":"publisher","key":"e_1_2_11_79_1","DOI":"10.1124\/jpet.117.245167"},{"doi-asserted-by":"publisher","key":"e_1_2_11_80_1","DOI":"10.1124\/jpet.102.039867"},{"doi-asserted-by":"publisher","key":"e_1_2_11_81_1","DOI":"10.1016\/j.exer.2015.07.007"},{"doi-asserted-by":"publisher","key":"e_1_2_11_82_1","DOI":"10.1167\/iovs.15-16378"},{"doi-asserted-by":"publisher","key":"e_1_2_11_83_1","DOI":"10.1371\/journal.pone.0159776"},{"doi-asserted-by":"publisher","key":"e_1_2_11_84_1","DOI":"10.1167\/iovs.17-23159"},{"doi-asserted-by":"publisher","key":"e_1_2_11_85_1","DOI":"10.1248\/bpbreports.4.1_1"},{"doi-asserted-by":"publisher","key":"e_1_2_11_86_1","DOI":"10.1021\/acsmedchemlett.4c00130"},{"key":"e_1_2_11_87_1","first-page":"2458","article-title":"The melatonin antagonist Luzindole protects retinal photoreceptors from light damage in the rat","volume":"39","author":"Sugawara T","year":"1998","journal-title":"Invest Ophthalmol Vis Sci"},{"doi-asserted-by":"publisher","key":"e_1_2_11_88_1","DOI":"10.1167\/iovs.10-6304"},{"doi-asserted-by":"publisher","key":"e_1_2_11_89_1","DOI":"10.1371\/journal.pone.0032472"},{"doi-asserted-by":"publisher","key":"e_1_2_11_90_1","DOI":"10.1016\/0896-6273(95)90172-8"},{"doi-asserted-by":"publisher","key":"e_1_2_11_91_1","DOI":"10.1038\/s41419-017-0171-8"},{"doi-asserted-by":"publisher","key":"e_1_2_11_92_1","DOI":"10.1073\/pnas.2221045120"},{"doi-asserted-by":"publisher","key":"e_1_2_11_93_1","DOI":"10.1073\/pnas.89.24.12093"},{"doi-asserted-by":"publisher","key":"e_1_2_11_94_1","DOI":"10.3389\/fncel.2021.647541"},{"volume-title":"Webvision: The Organization of the Retina and Visual System","year":"2020","author":"Popova E","key":"e_1_2_11_95_1"},{"doi-asserted-by":"publisher","key":"e_1_2_11_96_1","DOI":"10.1016\/j.exer.2008.08.004"},{"doi-asserted-by":"publisher","key":"e_1_2_11_97_1","DOI":"10.1016\/j.cellsig.2015.06.008"},{"doi-asserted-by":"publisher","key":"e_1_2_11_98_1","DOI":"10.1111\/j.1471-4159.2009.05920.x"},{"doi-asserted-by":"publisher","key":"e_1_2_11_99_1","DOI":"10.1084\/jem.20190930"},{"doi-asserted-by":"publisher","key":"e_1_2_11_100_1","DOI":"10.1177\/096120330501400102"},{"doi-asserted-by":"publisher","key":"e_1_2_11_101_1","DOI":"10.1016\/j.ajo.2009.09.026"},{"volume-title":"Beta Blockers","year":"2023","author":"Farzam K","key":"e_1_2_11_102_1"},{"doi-asserted-by":"publisher","key":"e_1_2_11_103_1","DOI":"10.1007\/BF00170828"},{"doi-asserted-by":"publisher","key":"e_1_2_11_104_1","DOI":"10.1016\/j.preteyeres.2016.12.001"},{"doi-asserted-by":"publisher","key":"e_1_2_11_105_1","DOI":"10.1016\/j.jconrel.2023.07.028"},{"doi-asserted-by":"publisher","key":"e_1_2_11_106_1","DOI":"10.3390\/ijms24098045"},{"doi-asserted-by":"publisher","key":"e_1_2_11_107_1","DOI":"10.1208\/s12249-021-01977-0"},{"doi-asserted-by":"publisher","key":"e_1_2_11_108_1","DOI":"10.1111\/bcp.13794"},{"doi-asserted-by":"crossref","unstructured":"Samanta A Aziz AA Jhingan M Singh SR Khanani AM Chhablani J (2020) Emerging Therapies in Neovascular Age\u2010Related Macular Degeneration in 2020. Asia Pac J Ophthalmol 9 250\u2013259.","key":"e_1_2_11_109_1","DOI":"10.1097\/APO.0000000000000291"},{"unstructured":"Study of PAN\u201090806 Eye Drops Suspension for Neovascular AMD. Clinicaltrials.gov NCT03479372.","key":"e_1_2_11_110_1"},{"doi-asserted-by":"publisher","key":"e_1_2_11_111_1","DOI":"10.1016\/j.survophthal.2017.09.009"},{"doi-asserted-by":"publisher","key":"e_1_2_11_112_1","DOI":"10.1208\/s12248-010-9183-3"},{"doi-asserted-by":"publisher","key":"e_1_2_11_113_1","DOI":"10.3390\/pharmaceutics13010108"},{"doi-asserted-by":"publisher","key":"e_1_2_11_114_1","DOI":"10.1089\/jop.2019.0081"},{"doi-asserted-by":"publisher","key":"e_1_2_11_115_1","DOI":"10.1371\/journal.pone.0042754"},{"doi-asserted-by":"publisher","key":"e_1_2_11_116_1","DOI":"10.1007\/s00210-022-02287-3"}],"container-title":["FEBS Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/febs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/1873-3468.70107","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T03:57:00Z","timestamp":1758686220000},"score":1,"resource":{"primary":{"URL":"https:\/\/febs.onlinelibrary.wiley.com\/doi\/10.1002\/1873-3468.70107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,9]]},"references-count":115,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1002\/1873-3468.70107"],"URL":"https:\/\/doi.org\/10.1002\/1873-3468.70107","archive":["Portico"],"relation":{},"ISSN":["0014-5793","1873-3468"],"issn-type":[{"type":"print","value":"0014-5793"},{"type":"electronic","value":"1873-3468"}],"subject":[],"published":{"date-parts":[[2025,7,9]]},"assertion":[{"value":"2025-04-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}